Immune complex analysis in active lyme disease

Steven E. Schutzer, P. K. Coyle

Research output: Contribution to journalArticle

Abstract

Lyme disease (LD) is a growing infectious disease. Assays that can detect active infection early are needed to allow appropriate antibiotic therapy to begin when there is the best chance for a cure. The most frequently used assays are those based on antibodies to Borrelia burgdorferi or its variants, the causative agent of LD. However, an antibody test at a single time point only measures exposure, not necessarily an active infection. In contrast, antibodies that are bound to a target antigen in a circulating immune complex form do indicate active infection. Here, we present data supporting the use of such assays in LD.

Original languageEnglish (US)
Pages (from-to)213-224
Number of pages12
JournalForum on Immunopathological Diseases and Therapeutics
Volume7
Issue number3-4
DOIs
StatePublished - Jan 1 2016

Fingerprint

Lyme Disease
Antigen-Antibody Complex
Assays
Antibodies
Infection
Borrelia burgdorferi
Communicable Diseases
Anti-Bacterial Agents
Antigens
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Biochemistry
  • Molecular Medicine
  • Genetics

Cite this

@article{9c0c058abe4149e69da268b76b8e5cfe,
title = "Immune complex analysis in active lyme disease",
abstract = "Lyme disease (LD) is a growing infectious disease. Assays that can detect active infection early are needed to allow appropriate antibiotic therapy to begin when there is the best chance for a cure. The most frequently used assays are those based on antibodies to Borrelia burgdorferi or its variants, the causative agent of LD. However, an antibody test at a single time point only measures exposure, not necessarily an active infection. In contrast, antibodies that are bound to a target antigen in a circulating immune complex form do indicate active infection. Here, we present data supporting the use of such assays in LD.",
author = "Schutzer, {Steven E.} and Coyle, {P. K.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1615/ForumImmunDisTher.2017019621",
language = "English (US)",
volume = "7",
pages = "213--224",
journal = "Forum on Immunopathological Diseases and Therapeutics",
issn = "2151-8017",
publisher = "Begell House Inc.",
number = "3-4",

}

Immune complex analysis in active lyme disease. / Schutzer, Steven E.; Coyle, P. K.

In: Forum on Immunopathological Diseases and Therapeutics, Vol. 7, No. 3-4, 01.01.2016, p. 213-224.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Immune complex analysis in active lyme disease

AU - Schutzer, Steven E.

AU - Coyle, P. K.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Lyme disease (LD) is a growing infectious disease. Assays that can detect active infection early are needed to allow appropriate antibiotic therapy to begin when there is the best chance for a cure. The most frequently used assays are those based on antibodies to Borrelia burgdorferi or its variants, the causative agent of LD. However, an antibody test at a single time point only measures exposure, not necessarily an active infection. In contrast, antibodies that are bound to a target antigen in a circulating immune complex form do indicate active infection. Here, we present data supporting the use of such assays in LD.

AB - Lyme disease (LD) is a growing infectious disease. Assays that can detect active infection early are needed to allow appropriate antibiotic therapy to begin when there is the best chance for a cure. The most frequently used assays are those based on antibodies to Borrelia burgdorferi or its variants, the causative agent of LD. However, an antibody test at a single time point only measures exposure, not necessarily an active infection. In contrast, antibodies that are bound to a target antigen in a circulating immune complex form do indicate active infection. Here, we present data supporting the use of such assays in LD.

UR - http://www.scopus.com/inward/record.url?scp=85049888238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049888238&partnerID=8YFLogxK

U2 - 10.1615/ForumImmunDisTher.2017019621

DO - 10.1615/ForumImmunDisTher.2017019621

M3 - Article

AN - SCOPUS:85049888238

VL - 7

SP - 213

EP - 224

JO - Forum on Immunopathological Diseases and Therapeutics

JF - Forum on Immunopathological Diseases and Therapeutics

SN - 2151-8017

IS - 3-4

ER -